Skip to main content
Clinical Trials/EUCTR2018-002466-39-NL
EUCTR2018-002466-39-NL
Active, not recruiting
Phase 1

Morphine or Fentanyl for Refractory dyspnea in COPD - MoreFoRCOPD

niversity Medical Center Groningen0 sites60 target enrollmentNovember 19, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Sponsor
niversity Medical Center Groningen
Enrollment
60
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2018
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • COPD GOLD class III or IV, according to GOLD criteria.
  • \- Post\-bronchodilatation FEV1/FVC \< 70% and FEV1 \< 50% pred.
  • Complaints of refractory dyspnea as established by patient and doctor.
  • mMRC score \= 3\.
  • Life expectancy of \= 2 months.
  • Optimized standard therapy according to Dutch LAN guideline for diagnosis and treatment of COPD.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 30

Exclusion Criteria

  • Other severe disease with chronic pain or chronic dyspnea (a non\-susbstantial component of left sided heart failure is acceptable).
  • Current use of opioids for whatever indication
  • Allergy / intolerance for opioids
  • Psychiatric disease, not related to severe COPD.
  • Exacerbation of COPD eight weeks prior to inclusion or between screening and randomization.
  • Problematic (leading to medical help or social problems) substance abuse during the last five years.
  • Active malignancy, with the exception of planocellular or basal cell carcinoma of the skin.
  • eGFR \<15 ml/min

Outcomes

Primary Outcomes

Not specified

Similar Trials